Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Abstract

Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations.

EGFR inhibition in NSCLC: New findings…. and opened questions?

“…However we should take into account that such study has met two (PFS and TTF) of the three co-primary endpoints, overall showing a significant reduction of 25% in the risk of PD, with about ¼ of patients reaching a significant PFS benefit >6 months with afatinib. Both TTF and PFS as well as OS data reported in LL7 are similar and consistent to those observed in other randomized studies of afatinib in first-line (Sequist et al, 2013;Wu et al, 2014), suggesting a potential superiority of this drug. Furthermore we can't exclude that final OS data, including also late censored events, might reach the statistical significance, definitively confirming the benefit observed in both PFS and TTF, which usually are more informative about first-line treatment efficacy.…”

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

“…However the management of advanced NSCLC has significantly improved during last decade. Innovative oral targeted molecules, such as the anti-EGFR tyrosine kinase inhibitors (TKIs), gefitinib, erlotinib, and afatinib, or the ALK inhibitor, crizotinib, have shown their superiority in terms of response rate, progression-free survival (PFS) and quality of life (QoL) compared with standard chemotherapy for tumours harbouring an activating EGFR mutation or ALK-rearrangement, respectively [1][2][3][4][5].…”

The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials

“…Based on results from seven prospective phase III randomized trials comparingfirst-line epidermal growthfactor receptor(EGFR) tyrosine kinase inhibitors (TKIs) to platinum-doublet chemotherapy as first-line treatment of non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (EGFRm), it is now well-established that EGFR TKI offers superior improvement in progression-free survival (PFS) [1][2][3][4][5][6][7]. Exploratory univariate analyses of three of the seven clinical trials (WJTOG3405, EURTAC, and LUX-Lung-3 [LL3]) suggested that EGFRm NSCLC patients who had a previous smoking history (former or current smoker) did not seem to derive a statistical PFS improvement when EGFR TKI was compared with platinum-doublet chemotherapy.…”